| scholarly article | Q13442814 |
| P50 | author | Hedvig Hricak | Q5697714 |
| Debra A Goldman | Q95975741 | ||
| Chaya S Moskowitz | Q100738671 | ||
| Victor Reuter | Q114316779 | ||
| Kristen L Zakian | Q114407271 | ||
| James A Eastham | Q115151513 | ||
| Junting Zheng | Q117268343 | ||
| Oğuz Akın | Q37842477 | ||
| Amita Shukla-Dave | Q91079106 | ||
| Hebert Alberto Vargas | Q94915686 | ||
| P2093 | author name string | Peter T Scardino | |
| Jingbo Zhang | |||
| Kent Kanao | |||
| P2860 | cites work | The Measurement of Observer Agreement for Categorical Data | Q26778373 |
| Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy | Q30983669 | ||
| Prostate specific antigen: a decade of discovery--what we have learned and where we are going | Q33690182 | ||
| Evolution from active surveillance to focal therapy in the management of prostate cancer. | Q33933490 | ||
| Critical review of prostate cancer predictive tools | Q34104562 | ||
| Contemporary trends in low risk prostate cancer: risk assessment and treatment | Q34330041 | ||
| The changing face of low-risk prostate cancer: trends in clinical presentation and primary management | Q34380870 | ||
| Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? | Q34534796 | ||
| Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness | Q34995967 | ||
| Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer | Q35722781 | ||
| Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms | Q36339473 | ||
| Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging | Q36434291 | ||
| How good is MRI at detecting and characterising cancer within the prostate? | Q36536899 | ||
| Imaging of prostate cancer | Q36678290 | ||
| Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer | Q36721080 | ||
| Imaging prostate cancer: a multidisciplinary perspective | Q36773229 | ||
| Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. | Q36837246 | ||
| Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer | Q36928846 | ||
| Will focal therapy become a standard of care for men with localized prostate cancer? | Q36983662 | ||
| The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis | Q37054328 | ||
| Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study | Q37145968 | ||
| Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging | Q37404915 | ||
| MRI for men undergoing active surveillance or with rising PSA and negative biopsies | Q37798723 | ||
| The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? | Q39694955 | ||
| Active surveillance for the management of prostate cancer in a contemporary cohort | Q39843996 | ||
| Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings | Q40896164 | ||
| MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease | Q41911549 | ||
| Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens | Q43864003 | ||
| Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer | Q44199886 | ||
| Careful Selection and Close Monitoring of Low-Risk Prostate Cancer Patients on Active Surveillance Minimizes the Need for Treatment | Q46770518 | ||
| Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer | Q47385607 | ||
| Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension | Q49168162 | ||
| Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. | Q52865420 | ||
| ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. | Q53472048 | ||
| The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis | Q57392760 | ||
| Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer | Q71606146 | ||
| Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications | Q71975828 | ||
| Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome | Q79426082 | ||
| Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly | Q82015782 | ||
| Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme | Q82984543 | ||
| Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance | Q84798910 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 478-487 | |
| P577 | publication date | 2012-09-05 | |
| P1433 | published in | Radiology | Q3285690 |
| P1476 | title | Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study | |
| P478 | volume | 265 |
| Q39024065 | Are magnetic resonance imaging undetectable prostate tumours clinically significant? Results of histopathological analyses |
| Q39211272 | Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer |
| Q57784098 | Computed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection |
| Q102377648 | Correlation of Stiffness of Prostate Cancer Measured by Shear Wave Elastography with Grade Group: A Preliminary Study |
| Q38109810 | Defining the threshold for significant versus insignificant prostate cancer. |
| Q50661010 | Detecting positive surgical margins: utilisation of light-reflectance spectroscopy on ex vivo prostate specimens. |
| Q33783620 | Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers |
| Q44248079 | Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla |
| Q41829663 | Exponential apparent diffusion coefficient in evaluating prostate cancer at 3 T: preliminary experience |
| Q38104639 | Functional and molecular imaging of localized and recurrent prostate cancer. |
| Q55381843 | Genes involved in prostate cancer progression determine MRI visibility. |
| Q53064739 | Image quality and cancer visibility of T2-weighted magnetic resonance imaging of the prostate at 7 Tesla. |
| Q50047697 | Information of prostate biopsy positive core: does it affect MR detection of prostate cancer on using 3T-MRI? |
| Q38671168 | Is contrast enhancement needed for diagnostic prostate MRI? |
| Q40133335 | Magnetic resonance spectroscopy imaging-directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate-specific antigen between 4-10 ng/mL and normal digital rectal examination |
| Q62050250 | Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer |
| Q40206375 | Multiparametric MRI for prostate cancer detection: performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL. |
| Q29037908 | PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2 |
| Q50209068 | PSA screening - for whom and when? |
| Q37709638 | Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer |
| Q37626492 | Predictive role of Trimprob associated with multiparametric MRI in the diagnosis of prostate cancer |
| Q47796911 | Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy. |
| Q37009160 | Prospective Pilot Trial to Evaluate a High Resolution Diffusion-Weighted MRI in Prostate Cancer Patients |
| Q55709236 | Prostate Cancer Detection with Multiparametric MRI: A Comparison of 1 M-Concentration Gadobutrol with 0.5 M-Concentration Gadolinium-Based Contrast Agents. |
| Q52665654 | Prostate Imaging-Reporting and Data System Version 2: Beyond Prostate Cancer Detection. |
| Q36879999 | Prostate MRSI predicts outcome in radical prostatectomy patients |
| Q57780548 | Prostate cancer imaging |
| Q38408501 | Prostate-specific antigen-based prostate cancer screening: Past and future |
| Q37746751 | Restriction spectrum imaging improves MRI-based prostate cancer detection |
| Q31131775 | Review of Prostate Imaging Reporting and Data System version 2. |
| Q99406948 | Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer |
| Q38089710 | Role of MRI in prostate cancer detection |
| Q40884788 | The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. |
| Q38930394 | The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer |
| Q26849794 | The role of magnetic resonance imaging in the diagnosis and management of prostate cancer |
| Q30995961 | Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference |
| Q52878871 | [MRI of the prostate]. |
| Q87366424 | [Prostate cancer] |
Search more.